Key result
Antidepressants linked to ~19% lower risk of developing hyperlipidemia in patients with depression.
Why the study?
Depression increases CVD risk and hyperlipidemia is a risk factor for CVD, but the association between antidepressant medications and CVD remains controversial.
Do antidepressant medications reduce the risk of developing hyperlipidemia in patients with depression?
Cohort (n=76,644)
Yes
Do antidepressant medications reduce the risk of developing hyperlipidemia in patients with depression?
Antidepressant medications may reduce the risk of developing hyperlipidemia in patients with depression, potentially through downregulation of lipogenesis-related genes.
Answers are grounded in this paper and cite their sources.
May suggest ADM benefit for hyperlipidemia in depression; hypothesis-generating and requires RCTs before practice change.
BACKGROUND: Depression increases the risk of cardiovascular disease (CVD). The association between antidepressant medications (ADMs) and CVD remains controversial. Hyperlipidemia is a risk factor for CVD. We conducted a nationwide population-based retrospective cohort study to examine depression and ADM use on the risk of developing hyperlipidemia. The effects of ADMs on the expression of lipogenesis-related hepatic genes were also evaluated. METHODS: We obtained data from the Longitudinal Health Insurance Database of Taiwan on patients with new-onset depression and a comparison cohort without depression. A Cox proportional hazards regression model was used to analyze the differences in the risk of developing hyperlipidemia between these two cohorts. We also examined the influence of ADMs on the expression of lipogenesis-related hepatic genes. RESULTS: After adjustment for comorbidities and confounding factors, the case group (N = 38,322) had a higher risk for hyperlipidemia than that of the control cohort (N = 38,322) [adjusted hazards ratio (aHR) =1.16]. Patients with depression who did not receive ADM therapy exhibited a significantly higher risk of hyperlipidemia (aHR = 1.61). However, in patients with depression treated with ADMs, the risk of developing hyperlipidemia was significantly lowered compared to the patients without ADMs (all aHR < 0.81). Gene expression analysis indicated that ADMs downregulated the expression of lipogenesis-related hepatic genes. LIMITATIONS: Unmeasured confounding risk factors for hyperlipidemia might not have been included in the study. CONCLUSIONS: ADMs reduced hyperlipidemia risk in patients with depression, partly by downregulating the expression of lipogenesis-related genes and improving the patients' lipid profiles. Early diagnosis and management of hyperlipidemia would further facilitate the prevention of CVD.
No takes yet. Share an insight, caveat, or question.
Tien et al. (2021) conducted a cohort in Depression (n=76,644). Antidepressant medications (ADMs) vs. No ADMs / No depression was evaluated on Risk of developing hyperlipidemia (aHR < 0.81). Antidepressant medications lowered the risk of developing hyperlipidemia in patients with depression compared to patients without ADMs.
Synapse has enriched 10 related papers. Consider them for comparative context: